MTAP alterations favor GSC formation with increased expression of the aggressiveness marker CD133 (Hansen et al., 2019), which is associated with poor clinical outcome of GBM patients (Zeppernick et al., 2008). This evidence concerns the gene MTAP and glioblastoma.